News - BRAF V600E - LARVOL VERI

22h

Concomitant RAS and BRAF V600E Mutations in Unresectable Metastatic CRC: A Case of Long-term Survival. (PubMed, J Anus Rectum Colon)

Moreover, reports on the long-term survival of patients with unresectable mCRC with concurrent mutations are lacking. The present study reports a rare case of long-term survival of over 39 months in a patient with mCRC harboring both RAS and BRAF V600E mutations, where chemotherapy alone was effective without surgical resection of the primary or metastatic lesions.

22 hours ago

Journal

BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)

BRAF V600E • BRAF V600

Evaluating the Molecular Landscape by Multigene Testing in Preoperative BRAF V600E-Positive Thyroid Nodules: A Multicenter Study (ChiCTR2500112247)

P=N/A, N=400, Not yet recruiting, Renji Hospital, School of Medicine in Shanghai Jiao Tong University, Shanghai; Renji Hospital, School of Medicine in Shanghai Jiao Tong University, Sh

3 days ago

New trial

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600

A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping (ChiCTR2500111407)

P=N/A, N=55, Not yet recruiting, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital

3 days ago

New trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NRG1 (Neuregulin 1) • VEGFA (Vascular endothelial growth factor A) • RNF43 (Ring Finger Protein 43) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • RET fusion • FGFR2 mutation • PALB2 mutation • FGFR2 fusion • MET mutation • IDH mutation + BRAF V600E • IDH mutation + NTRK fusion

An Open-Label, Single-Center, Multi-Cohort, Phase II Study Evaluating the Safety and Efficacy of Vebreltinib-Based Combination Therapy in Previously Treated Patients with Locally Advanced or Metastatic MET-Overexpressing Non-Small Cell Lung Cancer (ChiCTR2500112942)

P2, N=52, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

3 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • ALK rearrangement • MET exon 14 mutation • MET overexpression • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • MET mutation • MET expression • RET rearrangement • NTRK fusion

docetaxel • Jiataile (sacituzumab tirumotecan) • bozitinib (APL-101)

A single-arm,single-center, phase II clinical study of Aipalolitovorelizumab (QL1706) combined with bevacizumab and chemotherapy (FOLFOXIRI) as first-line treatment for MSS/pMMR metastatic colorectal cancer with BRAF V600E mutation (ChiCTR2500111888)

P2, N=30, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

3 days ago

New P2 trial

BRAF (B-raf proto-oncogene)

BRAF V600E

Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab)

An Exploratory Study on the Treatment of Anaplastic Thyroid Carcinoma with Camrelizumab Combined with Apatinib and Capecitabine (ChiCTR2500113785)

P2, N=20, Completed, Sichuan Cancer Hospital; Sichuan Cancer Hospital

3 days ago

New P2 trial

PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600

AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine

Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-B01D1 for Injection in Patients with Locally Advanced or Metastatic Solid Tumors (ChiCTR2500113663)

P1, N=500, Not yet recruiting, Sun Yat-sen University Cancer Center; Sichuan Baili Pharmaceutical Co., Ltd.

3 days ago

New P1 trial

BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • MET exon 14 mutation • ALK fusion • EGFR L861Q • RET mutation • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • KRAS G12 • NTRK fusion

izalontamab brengitecan (BL-B01D1)

A Phase I Clinical Study Evaluating the Safety and Tolerability of CEL001 Injection in the Treatment of Advanced Solid Tumors (ChiCTR2600116105)

P1, N=10, Recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Guangzhou Celling Biological Technology Co., Ltd.

3 days ago

New P1 trial

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600

Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147). (PubMed, J Clin Oncol)

Evaluation of ctDNA in resected stage III CC using a tissue-free assay provided robust and independent prognostic value. Higher ctDNA burden, dMMR, and specific mutations defined poor prognostic groups among ctDNA-positive patients.

4 days ago

P3 data • Journal • Circulating tumor DNA

FLT1 (Fms-related tyrosine kinase 1) • PREX2 (Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 2)

BRAF V600E • MSI-H/dMMR • BRAF V600

Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium

Remission of metastatic duodenal cancer after treatment with BRAF inhibitor (PubMed, Ugeskr Laeger)

Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the importance of molecular profiling in rare cancers. Further research is needed on the effect and safety of targeted therapy for small bowel adenocarcinoma.

4 days ago

Journal

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600

Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)

Targeting BRAF in cancers - from molecular diagnostics to personalized therapy. (PubMed, BioTechnologia (Pozn))

NGS, particularly comprehensive genomic profiling, provides the broadest and most detailed genetic data, although simpler laboratory techniques remain popular due to their accessibility and straightforward protocols. Further research into resistance mechanisms and combination therapies, as well as the integration of circulating tumor DNA (ctDNA) in diagnostics, is needed to fully realize the potential of personalized treatment in BRAF-driven tumors.

4 days ago

Journal • IO biomarker

BRAF (B-raf proto-oncogene)

BRAF V600E

Rare co-occurrence of gastrointestinal stromal tumors and leiomyomas: A case report and review of the literature. (PubMed, Exp Ther Med)

The present study highlights that clinicians should be aware that GIST and gastric leiomyoma can coexist in the same SEL to avoid misdiagnosis and mistreatment. In the face of the escalating drug resistance rate of GIST, researchers may derive some novel insights from the present findings for GIST treatment and management.

5 days ago

Journal

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600